OSE Immunotherapeutics Announces Four Poster Presentations of Neoepitope Combination Tedopi in Immuno-Oncology at ASCO 2022
23.05.2022 - Regulatory News: OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione Ricerca Traslazionale), today announced four poster presentations* featuring ... Seite 1
Source: wallstreet-online.de